Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Respir Investig ; 61(1): 110-115, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36470803

ABSTRACT

BACKGROUND: There are no evidence-based reports on the proper duration of antimicrobial therapy following video-assisted thoracoscopic surgery debridement (VATS-D) in thoracic empyema (TE) or complicated parapneumonic effusion (PPE). This study aimed to investigate the optimal duration of antimicrobial therapy after VATS-D. METHODS: Between January 2011 and December 2019, 33 patients corresponding to American College of Chest Physicians (ACCP) category 3 or 4 undergoing VATS-D were included. The times until the body temperature (BT) was confirmed to be less than 37.5 °C and 37.0 °C, white blood cell count (WBC) less than 10,000/µl, segmented neutrophils (seg) less than 80%, and C-reactive protein (CRP) level less than 25% of the preoperative value were retrospectively analyzed. RESULTS: The median time from the onset of TE/PPE to surgery was 13 days. The median durations of preoperative and postoperative antibiotic use were five and seven days, respectively. Major complications occurred in four cases (three and one cases of respiratory failure and cerebral infarction, respectively). The median postoperative hospital stay was 14 days. Recurrence or progression to chronic empyema was seen in four cases. The median numbers of days until the conditions were met were three days for BT < 37.5 °C, six days for BT < 37.0 °C, four days for WBC<10,000, seven days for seg<80% and seven days for CRP<25%. CONCLUSIONS: The proper duration of antimicrobial therapy after VATS-D for TE/PPE is approximately three to seven days. Urgent VATS-D may shorten the total antibiotic usage.


Subject(s)
Empyema, Pleural , Pleural Effusion , Humans , Thoracic Surgery, Video-Assisted , Retrospective Studies , Empyema, Pleural/drug therapy , Empyema, Pleural/etiology , Empyema, Pleural/surgery , Anti-Bacterial Agents/therapeutic use
2.
Gen Thorac Cardiovasc Surg ; 63(7): 401-5, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25868520

ABSTRACT

INTRODUCTION: As the population ages, the age of patients undergoing thoracic surgery increases, and elderly patients often have more comorbidities than younger patients. METHODS: This retrospective study observed preoperative comorbidities, surgical procedures and postoperative morbidity and mortality after lung cancer surgery in patients 80 years of age or older. The medical records of lung cancer patients 80 years of age or older who underwent surgery from January 2003 to December 2012 were reviewed. RESULTS: There were 49 patients (27 males, 22 females), with a median age of 83 years. Thirty patients underwent major pulmonary resection and 18 patients underwent limited pulmonary resection. The median Charlson comorbidity index was 3. Although approximately two-thirds of the patients (20 patients; 40.8%) experienced some kind of postoperative morbidity, more than 80% of the complications were grade 1 or 2 according to the Clavien-Dindo classification. Cerebrovascular disease and chronic obstructive pulmonary disease were significantly associated with moderate-to-severe complications. Postoperative death was observed in two cases (4.1%). In addition, an increased American Society of Anesthesiologists classification score and past history of myocardial infarction, congestive heart failure and/or diabetes mellitus with end-organ damage were significantly associated with mortality. The overall survival rate was 79.6% at 3 years and 53.1% at 5 years. CONCLUSIONS: Thoracic surgery shows acceptable morbidity and mortality in patients 80 years of age or older. Patients 80 years of age or older should be offered the best treatments, including surgery, with careful patient evaluation and selection.


Subject(s)
Lung Neoplasms/surgery , Adenocarcinoma/complications , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Aged, 80 and over , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Comorbidity , Female , Health Services for the Aged , Humans , Japan , Lung Neoplasms/complications , Lung Neoplasms/mortality , Male , Neoplasm Staging , Pulmonary Surgical Procedures/methods , Retrospective Studies , Risk Factors , Survival Rate , Treatment Outcome
4.
Asian Cardiovasc Thorac Ann ; 23(6): 710-2, 2015 Jul.
Article in English | MEDLINE | ID: mdl-24585314

ABSTRACT

Primary effusion lymphoma is a type of B-cell lymphoma that is primarily related to human immunodeficiency virus. Thoracic surgeons rarely encounter this disease because of its rarity. We herein report a case of primary effusion lymphoma which required surgery for successful treatment. An 83-year-old man was admitted to our hospital with signs of cardiac tamponade. A radiological examination revealed a pericardial effusion. Performing percutaneous pericardiocentesis was difficult due to the patient's anatomical features. We performed open cardiocentesis under general anesthesia. A cytologic examination revealed primary effusion lymphoma. The patient underwent chemotherapy, resulting in complete remission.


Subject(s)
Heart Neoplasms/diagnosis , Lymphoma, Primary Effusion/diagnosis , Thoracic Surgical Procedures/methods , Aged, 80 and over , Diagnosis, Differential , Heart Neoplasms/drug therapy , Heart Neoplasms/surgery , Humans , Lymphoma, Primary Effusion/drug therapy , Lymphoma, Primary Effusion/surgery , Male , Pericardiocentesis
SELECTION OF CITATIONS
SEARCH DETAIL
...